BioLamina

Michele Mosciski MD

🇷🇺 Russia

8.9

Reviewed: July 3, 2024

• - Stability Studies
• - 18 months January 2023 - June 2024
• - Pharmaceutical Company

The stability studies were conducted with precision, and the reporting was clear and thorough. The results provided us with the necessary data to proceed with our regulatory submissions confidently.

Melanie Tillman IV

🇧🇷 Brazil

8.8

Reviewed: May 15, 2024

• - Companion Diagnostics Development
• - 16 weeks January - May 2024
• - Pharmaceutical Company

The development of companion diagnostics was of high quality, and the project was delivered on time. The team's technical expertise and understanding of the regulatory environment were key to the success of the project.

Arlene Collins

🇺🇸 United States

6.3

Reviewed: November 7, 2024

• - Stability Studies
• - 16 months July 2023 - November 2024
• - Pharmaceutical Company

The stability studies conducted were lacking in detail, and we had to perform additional validation to ensure the results were reliable. This added extra time and cost to the project. The team was responsive to feedback, but the initial work was subpar.

Alicia Krajcik

🇳🇱 Netherlands

9.1

Reviewed: August 11, 2023

• - Clinical Data Management
• - 6 weeks June - July 2023
• - CRO

The data management services were delivered on time and with great accuracy. Collaboration with the team was smooth, and they were always available to address any concerns or questions we had. We were very satisfied with the outcome.

Wallace Tillman

🇺🇸 United States

8.9

Reviewed: March 3, 2023

• - Regulatory Submission
• - 6 weeks February 2023
• - Biotech Startup

Our regulatory submission was handled with great care and expertise. The process was seamless, and their knowledge of the regulatory landscape was impressive. The team's support was invaluable, and I would not hesitate to use their services again.